Compare Allstate Corp (ALL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Allstate Corp trades at $252.5 (market cap $64.77B), while State Street SPDR S&P Biotech ETF trades at $155.37. The key difference: Allstate Corp pays a 1.72% dividend while State Street SPDR S&P Biotech ETF pays none, and Allstate Corp is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| ALL | XBI | |
|---|---|---|
Market Cap | $64.77B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $251.61 | $164.28 |
52-Week Low | $190.00 | $85.16 |
Enterprise Value | $73.56B | — |
Dividend Yield | 1.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.
The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.
XBI, the SPDR S&P Biotech ETF, trades at $159.03, down 3.2% over the past day amid a broader market pullback, though it remains in a strong uptrend with a 17% gain over the past month. Technical indicators are bullish overall, but RSI levels suggest overbought conditions. The ETF's equal-weight exposure to biotech stocks drives high volatility and significant upside during sector rallies, with recent news highlighting booming biotech M&A and AI-driven drug discovery as key catalysts.
The outlook for XBI is positive given sector momentum and favorable deal activity, though its high beta and reliance on small- to mid-cap biotech stocks pose risks during market downturns. Analyst sentiment is neutral with a single hold rating, reflecting caution amid elevated valuations. Investors should weigh the sector's growth potential against inherent volatility and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
